Dimethyltryptamine

Colorado is implementing a regulated psychedelic therapy program, allowing licensed use of psilocybin mushrooms starting 2025. Voter-approved, it includes screening, supervised sessions, and post-therapy integration. The program aims to address mental health crises, with applications for licenses already underway. Fees and regulations are set, emphasizing safety and accessibility.

Colorado is implementing a regulated psychedelic therapy program using psilocybin, starting in 2025. Licensed facilitators will oversee therapeutic sessions in secure environments. The program, approved by voters, aims to address mental health issues, with specific regulations and licensing for cultivation, manufacturing, and healing centers. Fees and training programs for facilitators have been established, with the state managing the program's regulatory framework.

Colorado's voter-approved natural medicine program, starting in 2025, allows licensed therapeutic use of psilocybin in regulated environments. Facilitators will guide participants through a structured process, including assessment, preparation, administration, and integration. The program aims to address mental health issues, with psilocybin recognized as a breakthrough therapy for depression. State agencies regulate the program, with licensing fees and training requirements established for facilitators.

Colorado is implementing a regulated psilocybin therapy program, allowing licensed therapeutic sessions starting 2025. Voters approved this in 2022, following Oregon. Participants must undergo screening and sessions supervised by licensed facilitators. The program aims to address mental health issues, with psilocybin recognized as a breakthrough therapy for depression. State agencies regulate the program, with licensing fees and training requirements for facilitators.

Journalists predict 2025 will be pivotal for psychedelics, focusing on VA research, FDA's stance on MDMA-assisted therapy, state-level legalization efforts, and the impact of political changes. Key figures like VA's Dr. Shereef Elnahal and potential D.H.H.S. head Robert F. Kennedy Jr. could influence psychedelics' future. States like Colorado and Oregon are advancing psychedelic programs, while others consider similar initiatives.

Ryan Chrapko transformed his life using psilocybin, moving from substance abuse to mental health improvement. Colorado's Proposition 122 now allows clinical psychedelic use, offering therapeutic benefits for conditions like PTSD and depression, with professional guidance enhancing outcomes.

Celebrities like Aaron Rodgers and Kristen Bell are increasingly sharing their experiences with psychedelics for healing and self-discovery, highlighting therapeutic benefits such as reduced anxiety and depression. Despite potential risks and legal issues, research supports psychedelics' positive effects on mental health and creativity, with some advocating for regulated therapeutic use.

2024 saw significant drug policy changes, including Kamala Harris's pledge to federally legalize cannabis, and rescheduling of cannabis to Schedule III. Lenacapavir, a new HIV prevention drug, was named breakthrough of the year. Weight loss drugs like Ozempic and Wegovy showed potential for treating addiction and neurodegenerative diseases. Overdose deaths declined nationally for the first time since the 1990s, though racial disparities persist. Psychedelics faced setbacks with FDA not approving MDMA for PTSD and Massachusetts rejecting a ballot measure for home-use of psilocybin. The White House accused Syria's Assad of profiting from Captagon sales, leading to its destruction and potential relocation of manufacturing. 'Pink cocaine' gained popularity, posing risks due to its unknown composition.

In 2023, Biden Administration recommended cannabis reclassification, with progress continuing into 2024. The FDA rejected MDMA-assisted therapy for PTSD in August, with another clinical trial planned. Boulder's Cannabis Licensing and Advisory Board considered a marijuana concentrates ban, which the industry opposes. Colorado prepared for psychedelic healing centers, with training programs approved and licenses available from December. Naropa's psychedelic program was delayed but will be run by Memoru Center. Healing centers will initially use psilocybin and psilocin, with potential expansion to other substances in 2026.

DEA increases 2025 DMT production quota to 20,000 grams to support FDA-approved drug development, citing research needs and public comments. Several companies are exploring DMT for treating mental health conditions and brain injuries.